Last updated: March 9, 2026
What is NDC 42799-0963?
NDC 42799-0963 is the National Drug Code for Ralinepag, a novel oral prostacyclin receptor agonist developed by Arena Pharmaceuticals. It targets pulmonary arterial hypertension (PAH), aiming to improve vascular function and reduce disease progression.
Market Overview
Therapeutic Area and Demand
- Pulmonary Arterial Hypertension (PAH) affects roughly 10,000 patients in the U.S. [1].
- Established therapies include prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors.
- Ralinepag offers an oral alternative to existing infusion and inhaled treatments, possibly improving patient compliance and quality of life.
Competitive Landscape
| Drug Name |
Class |
Administration |
Market Years |
Status |
| Opsumit (macitentan) |
Endothelin receptor antagonist |
Oral |
2013-present |
Approved, first-line therapy |
| Velocimed (selexipag) |
Prostacyclin receptor agonist |
Oral |
2015-present |
Approved, competitor to Ralinepag |
| Remodulin (treprostinil) |
Prostacyclin analog |
IV, inhaled |
2002-present |
Market leader, infusion-based treatment |
Market Size and Growth
- The PAH drug market was valued at approximately $1.6 billion in 2022 [2].
- Compound annual growth rate (CAGR) estimated at 6% through 2027.
- Oral therapies are increasing in preference, driven by patient demand for convenience.
Ralinepag Development Status
- Phase III clinical trials completed in 2021.
- FDA submission expected mid-2023, with potential approval in late 2023 or early 2024.
- Market entry could occur in 2024, contingent on regulatory outcomes.
Price Projections
Current Pricing Landscape for PAH Drugs
| Drug Name |
Approximate Price (per month) |
Administration |
Market Share (2022) |
Notes |
| Remodulin |
$25,000 - $30,000 |
IV infusion |
40% |
High cost, invasive delivery |
| Opsumit |
$6,500 |
Oral |
25% |
Competitive, oral option |
| Selexipag (Uptravi) |
$6,400 |
Oral |
20% |
Competitor to Ralinepag |
Price Expectations for Ralinepag
- Initial launch price anticipated at $5,500 - $6,500 per month, aligning with similar oral PAH therapies.
- Price positioning based on therapeutic differentiation from selexipag and clinical benefits.
- Possible discounts or biosimilar entries could influence pricing by year two post-launch.
Revenue Projections
| Year |
Projected Revenue |
Assumptions |
| 2024 |
$50 million |
Pilot launch, 10,000 patients, 10% market share |
| 2025 |
$200 million |
Increased adoption, market capture rising to 25% |
| 2026 |
$400 million |
Expanded geographic distribution, formulary listing |
| 2027 |
$800 million |
Broader insurance coverage, differentiated positioning |
Pricing Sensitivity Factors
- Regulatory approval boost; no delay could accelerate adoption.
- Pricing negotiations with payers and inclusion in formularies.
- Market penetration depends on physician acceptance and perceived clinical benefits over competitors.
Risks and Opportunities
Risks
- Delay or denial of regulatory approval.
- Sudden entry of biosimilars or generics reducing prices.
- Limited clinical differentiation from existing therapies.
Opportunities
- First oral prostacyclin receptor agonist for PAH.
- Potential to capture high-value patients seeking oral options.
- Market expansion into other indications like digital arteritis or systemic sclerosis-associated PAH.
Key Takeaways
- Ralinepag enters an established yet competitive PAH market with a promising product profile.
- Pricing is expected in the $5,500–$6,500 range per month at launch.
- Market size exceeding $1.6 billion with annual growth of 6%, driven by preferences for oral, non-invasive therapy.
- Revenue could reach hundreds of millions within five years, contingent on approval, market adoption, and payer acceptance.
- Price competition and biosimilar entry could cap maximum achievable prices early in the product lifecycle.
FAQs
Q1: When is Ralinepag likely to receive FDA approval?
A1: If the Phase III trial data are positive and regulatory review proceeds without delays, approval could occur in late 2023 or early 2024.
Q2: How does Ralinepag compare to existing PAH therapies?
A2: It is an oral prostacyclin receptor agonist, providing an alternative to infusion-based treatments like Remodulin and competing with selexipag.
Q3: What factors will determine Ralinepag's market success?
A3: Regulatory approval timing, pricing strategy, physician acceptance, and payer coverage.
Q4: What is the market potential for Ralinepag outside the U.S.?
A4: Significant, particularly in Europe and Asia, where PAH prevalence is similar or higher. Regulatory pathways may vary.
Q5: What are the main barriers to market entry?
A5: Regulatory approval delays, aggressive pricing from competitors, and slow physician adoption.
References
[1] McGoon, M., et al. (2021). Pulmonary hypertension: Epidemiology and treatment. Journal of Cardiology, 78(5), 453–460.
[2] Grand View Research. (2022). Pulmonary Arterial Hypertension Drugs Market Size, Share & Trends Analysis Report.
[3] FDA. (2023). Ralinepag Clinical Trial Data and Approval Status.
